Table 1.
Baseline characteristics for all patients.
| Variables | TACE-RFA (n = 209) | TACE (n = 195) | P value |
|---|---|---|---|
| Gender (male/female) | 184/25 | 165/30 | 0.384 |
| Age (years)# | 59.2 ± 4.0 (18–75) | 58.7 ± 4.0 (20–75) | 0.872 |
| HBsAg (+/−) | 180/29 | 176/19 | 0.221 |
| HCV (+/−) | 10/199 | 7/188 | 0.625 |
| ALT (U/L)# | 27.2 ± 12.0 (16.5–78.2) | 29.0 ± 11.9 (15.9–77.0) | 0.789 |
| ALB (g/L)# | 35.7 ± 3.0 (33.0–49.0) | 35.9 ± 3.4 (32.4–47.0) | 0.876 |
| Total bilirubin (μmol/L)# | 12.8 ± 4.2 (7.0–22.0) | 12.3 ± 4.5 (6.3–22.0) | 0.902 |
| GGT (U/L)# | 106.0 ± 51.0 (49.0–422.0) | 103.5 ± 61.0 (52.5–434.3) | 0.675 |
| Platelet count (×109/L)# | 125.2 ± 25.9 (75–401) | 130.2 ± 28.2 (80–403) | 0.710 |
| Prothrombin activity (%)# | 98.0 ± 19.0 (78–120) | 98.0 ± 18.4 (77–119) | 0.735 |
| AFP (ng/ml) | 0.762 | ||
| ≤400 | 123 | 111 | |
| >400 | 86 | 84 | |
| Tumor size (cm) | 0.840 | ||
| ≤3 | 125 | 114 | |
| >3 | 84 | 81 | |
| Tumor number | 0.447 | ||
| 1 | 58 | 61 | |
| >1 | 151 | 134 | |
| Child–Pugh class (A/B) | 189/20 | 180/15 | 0.596 |
| Antiviral treatment for hepatitis B (yes/no) | 108/101 | 99/96 | 0.921 |
#Data are represented in mean ± standard deviation. Data in parentheses are ranges. Except where indicated, data values represent the number of patients. TACE: transarterial chemoembolization; RFA: radiofrequency ablation; HBsAg: hepatitis B surface antigen; HCV: hepatitis C virus; ALT: alanine aminotransferase; ALB: albumin; GGT: γ-glutamyl transpeptidase; AFP: alpha fetoprotein.